LAGUNA HILLS, Calif., April 18, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, released today an interview-style QA article that discusses the company’s Cannabis Research Program with Mark L. Rabe, MD, the Director of PharmaCyte’s Cannabis Program Development.
Given the latest research recently presented by Dr. Hyslop and his colleagues at the University of Northern Colorado (UNC), what are your thoughts about the future of PharmaCyte’s Cannabis Research Program?
Dr. Mark Rabe: “The latest news from Dr. Hyslop and the UNC team was very encouraging. As a result, PharmaCyte’s Cannabis Research Program is in high gear. The UNC research focuses on developing targeted cannabinoid-based chemotherapy utilizing the Cell-in-a-Box® live-cell encapsulation technology.
“The therapy is designed to work by implanting encapsulated engineered cells in a blood vessel